Jae Park, MD

Outcomes With Obe-Cel in ALL: An Age-Based Analysis of the FELIX Trial

June 24th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss an age-based analysis of outcomes with obe-cel in acute lymphoblastic leukemia.

Dissecting the Impact of Obe-Cel on the ALL Treatment Paradigm

June 24th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss how the integration of obe-cel has affected the acute lymphoblastic treatment paradigm.

Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia

February 16th 2024

Dr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.

Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL

February 16th 2024

Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.

Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy

February 9th 2024

Dr. Park and co-panelists review the patient and disease characteristics, including patient age, high pre-apheresis disease burden, and bridging response to inotuzumab or blinatumomab among other variables that might best support consideration of post-CART19 maintenance therapy.

Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)

February 9th 2024

Dr. Roloff and faculty assess outcomes from the retrospective, multicenter ROCCA analysis (Real-world Outcomes Collaborative of CAR-T in Adult ALL) and propose some social determinants of health SDoH variables that bear further investigation.

Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion

February 2nd 2024

Dr. Roloff and colleagues offer expert opinion on optimizing treatment sequences for patients with relapsed or refractory ALL who have received two or more prior lines of therapy and the disease and patient factors that inform their treatment plans.

Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease

February 2nd 2024

Panelists evaluate PFS, OS, and the prognostic significance of negative MRD.

Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial

January 26th 2024

Dr. Bijal and colleagues discuss the objectives, clinical outcomes, and safety profile of the Phase 2 ZUMA 3 clinical trial, which evaluated treatment of adult patients with relapsed or refractory, B-precursor, acute lymphoblastic leukemia with the anti-CD-19/anti-CD20 bispecific CAR-T cell therapy, KTE-X19 (brexucabtagene autoleucel).

Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL

January 26th 2024

Drs. Roloff, Park, and Shah provide a brief overview of the current, CAR-T cell therapeutic landscape for relapsed or refractory acute lymphoblastic leukemia in adults with a particular focus on those who have completed two or more lines of prior therapy.

Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL

January 26th 2024

Faculty review the objectives of the 2023 ASH Insights Program on the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia.

Faculty Introductions

December 22nd 2023

Panelist introductions by Gregory Roloff, MD from the University of Chicago Comprehensive Cancer Center, Chicago, Illinois; Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, New York; and Bijal Shah, MD, from the Moffitt Cancer Center, Tampa, Florida.

The Future of R/R B-ALL Treatment

September 13th 2023

Jae Park, MD, wraps up his discussion by highlighting exciting investigational agents on the horizon for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice

September 6th 2023

Dr Jae Park shares his experience with using brexucabtagene autoleucel for patients with relapsed/refractory B-cell acute lymphoblastic leukemia in clinical practice since its FDA approval in October 2021.

Outcomes Data Following Brexucabtagene Autoleucel Therapy in Patients With R/R B-ALL

September 6th 2023

Jae Park, MD, explains how real-world CAR T-cell therapy data in patients with relapsed/refractory B-cell acute lymphoblastic leukemia shows high response rates but emphasizes the ongoing need for optimizing toxicity management, with trends toward earlier treatment and cell collection.

R/R B-ALL: Key Safety Outcomes From the Updated Analysis of the ZUMA-3 Trial

August 30th 2023

Dr Jae Park discusses managing cytokine release syndrome and the neurotoxicity side effects of CAR T-cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia through medications, disease burden reduction, and earlier intervention to prevent severe toxicities.

R/R B-ALL: Key Efficacy Outcomes From the Updated Analysis of the ZUMA-3 Trial

August 30th 2023

Jae Park, MD, reviews updated data from the ZUMA-3 trial on the use of the CAR T-cell therapy brexucabtagene autoleucel (brexu-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia, noting high remission rates, management of side effects like cytokine release syndrome, and post-CAR-T consolidation, including transplant.

Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL

August 22nd 2023

Dr Jae Park details the treatment options for relapsed/refractory B-cell acute lymphoblastic leukemia, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, with the treatment choice dependent on patient factors like comorbidities, disease burden, and transplant status.

Signs and Symptoms of B-Cell Acute Lymphoblastic Leukemia (B-ALL)

August 22nd 2023

Jae Park, MD, explains how B-cell acute lymphoblastic leukemia is diagnosed, and the testing done for detection of genetic abnormalities, which impacts treatment and prognosis.

Emerging Therapies for Adults with R/R B-ALL

June 28th 2022